Jefferies resumed coverage on RVL Pharmaceuticals with a new price target
$RVLP
Pharmaceuticals and Biotechnology
Health Care
Jefferies resumed coverage of RVL Pharmaceuticals with a rating of Hold and set a new price target of $2.50
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2022 | $2.50 | Hold | Jefferies |
| 4/5/2022 | $4.00 | Overweight | Barclays |
Lender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S. Subsidiaries to Continue as They Pursue Strategic Plan RVLP Ordinary Shares Expected to be Cancelled BRIDGEWATER, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc ("RVL" or "the Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy eyelid, in adults, today announced that certain of its U.S. operating subsidiaries, RevitaLid Pharmaceutical C
BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a fireside chat and host 1x1 investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference in New York City as follows: Date:Tuesday, September 12, 2023 Time:11:30 am ET Webcast:Click here To schedule a 1x1 investor meeting with the Company, please contact [email protected] at H.C. Wainwright. The live and archived webcast of the fireside chat will be accessible from the Company's website at www.rvlpharma.com, under the Investors & New
BRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, today announced that it has entered into definitive agreements for the purchase and sale of 11,870,846 of its ordinary shares (or ordinary share equivalents in lieu thereof) at a purchase price of $0.4212 per ordinary share (or ordinary share equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. The Company also agreed
SC 13D/A - RVL Pharmaceuticals plc (0001739426) (Subject)
SC 13D/A - RVL Pharmaceuticals plc (0001739426) (Subject)
SC 13D/A - RVL Pharmaceuticals plc (0001739426) (Subject)
-- UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity -- -- Executed financing amendment with Athyrium, which, subject to certain conditions, would provide meaningful flexibility as part of our ongoing strategy to invest in UPNEEQ and drive growth -- -- The Company is in discussions with strategic targets that could accelerate UPNEEQ sales, broaden the Company's portfolio and leverage the field force investment -- -- Second quarter 2023 UPNEEQ net product sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year pe
BRIDGEWATER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its second quarter 2023 financial results and provide a commercial update on Monday, August 14, 2023, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows: Date Monday, August 14, 2023Time 8:30 a.m. ETRegister* (audio only) Click hereW
-- First quarter 2023 UPNEEQ® net product sales grew 49%, or $2.9 million, over the prior year period to $8.8 million -- -- Enhanced operating leverage with a 32%, or $7.9 million, reduction in first quarter 2023 total operating expenditures from the prior year -- -- Majority of aesthetic orders in the first quarter, or 54%, represented reorder activity -- -- Approximately 4,800 cumulative unique medical aesthetics practices had placed orders for UPNEEQ through the end of the first quarter, a 12% increase from prior quarter end -- -- UPNEEQ Won "Best Eye Drop for Drooping Lids" NewBeauty in 13th Annual Beauty Awards, selected from among 10,000 entrants -- BRIDGEWATER, N.J., M
4 - RVL Pharmaceuticals plc (0001739426) (Issuer)
4 - RVL Pharmaceuticals plc (0001739426) (Issuer)
4 - RVL Pharmaceuticals plc (0001739426) (Issuer)
8-K - RVL Pharmaceuticals plc (0001739426) (Filer)
8-K - RVL Pharmaceuticals plc (0001739426) (Filer)
8-K - RVL Pharmaceuticals plc (0001739426) (Filer)
Jefferies resumed coverage of RVL Pharmaceuticals with a rating of Hold and set a new price target of $2.50
Barclays resumed coverage of RVL Pharmaceuticals with a rating of Overweight and set a new price target of $4.00